| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 10, 2025
Findings highlight the potential of new investigational waveforms for the all-in-one mapping and dual-energy ablation system in advancing treatment for ventricular arrhythmia patients
-
Mar 28, 2025
New investigational energy waveforms created specifically to target ventricular arrhythmias
Ventricular arrhythmia research will provide important clinical evidence using a new technology for patient population in need of new treatment options
-
Jan 17, 2025
Data include durability of PulseSelect integrated with the Affera system, same day discharge and zero fluoroscopy with Affera and Sphere-9™ Catheter
Highlights underscore positive momentum of commercial launch of Affera in the U.S. and continued strong adoption of PulseSelect globally
Real-world use continues to demonstrate safety, efficacy and efficiency of both PFA technologies amid global expansion
-
Oct 11, 2024
The VT research will provide important clinical evidence in an underserved patient population
-
Aug 22, 2024
Post-market data collection will add real-world experience to established safety, efficacy, and efficiency evidence profile